PRF Technologies Ltd. is a clinical-stage specialty pharmaceutical company based in Tel Aviv-Yafo, Israel, focused on reformulating established therapeutics for pain management. The company's primary development candidate is PRF-110, a viscous clear oil-based solution designed for direct instillation into surgical wounds to provide localized and extended post-operative analgesia. PRF-110 is currently in Phase 3 clinical trials for two indications: pain management following bunionectomy procedures and pain treatment in hernia repair operations.
The company operates as a development-stage entity with minimal commercial infrastructure. As of the latest available data, PRF Technologies maintains a headcount of two full-time employees and remains pre-revenue, with no established revenue streams. The organization is incorporated in Israel and listed on Nasdaq, reflecting its status as a publicly traded clinical-stage entity rather than an established commercial operation.
PRF Technologies was incorporated in 2007 and previously operated under the name PainReform Ltd., changing to its current designation in January 2026. The company's geographic focus and operations are centered in Israel, with development activities concentrated on advancing its clinical pipeline.
No 10-K filings found.